How Do You Solve a Problem like England's Cancer Drugs Fund?
The Cancer Drugs Fund (CDF) is a particular English approach to deal with rejections by the National Institute for Health and Care Excellence (NICE) for new cancer medicines.
The Cancer Drugs Fund (CDF) is a particular English approach to deal with rejections by the National Institute for Health and Care Excellence (NICE) for new cancer medicines. It’s now worth £280million a year - still a drop in the ocean compared to the £5 billion or so spent on cancer by the NHS in England. 55,000 patients have benefitted from the fund according to the Department of Health.
The CDF started out with positive headlines, but over time it’s fallen out of favour with policy makers (if indeed it was ever really supported outside of the elite who advise the Prime Minister). That’s because it busted its £200 million budget in the last financial year, by over £30 million. It was also supposed to be a temporary policy, ending in 2014, it’s now planned to be in place for 6 years, running from 2010 to 2016. At the same time, NICE has said that the CDF ‘makes no sense’ and wants to take the fund over. Even the King’s Fund Chief Economist, John Appleby, has come out against the fund, suggesting that it’s inequitable and inefficient.
The answer it seems is in tougher ‘re-evaluation’ of those drugs on the approved list, including consideration of their median cost, plus encouraging companies to offer discounts if they want to keep their drugs on the list. NHS England is hoping that a combination of these will keep it within it’s £280million budget. Drugs like Avastin, Erbitux, Perjeta, Afinitor, and Abraxane could be cut according to speculation in the media. Pressure is being brought to bear on the companies to offer better prices in order to keep them on the approved list.
That’s not all; NHS England will also be working with NICE, patient groups and the Association of the British Pharmaceutical Industry (ABPI) to ensure greater ‘alignment between CDF and NICE assessment processes’.
NHS England’s consultation closes on the 31st October 2014 and we’ll have to wait and see whether that leads to the changes NHS England hope for, or if as we’ve seen with NICE for Value Based Assessment (VBA), stakeholders put the brakes on the changes.
Leela Barham is an independent health economist. You can find out more about on her website and contact her at leels@btinternet.com
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
